Disease-Specific Quality Indicators for Outpatient Antibiotic Prescribing for Respiratory Infections (ESAC Quality Indicators) Applied to Point Prevalence Audit Surveys in General Practices in 13 European Countries

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Disease-Specific Quality Indicators for Outpatient Antibiotic Prescribing for Respiratory Infections (ESAC Quality Indicators) Applied to Point Prevalence Audit Surveys in General Practices in 13 European Countries. / Vellinga, Akke; Luke-Currier, Addiena; Garzón-Orjuela, Nathaly; Aabenhus, Rune; Anastasaki, Marilena; Balan, Anca; Böhmer, Femke; Lang, Valerija Bralić; Chlabicz, Slawomir; Coenen, Samuel; García-Sangenís, Ana; Kowalczyk, Anna; Malania, Lile; Tomacinschii, Angela; van der Linde, Sanne R.; Bongard, Emily; Butler, Christopher C.; Goossens, Herman; van der Velden, Alike W.

In: Antibiotics, Vol. 12, No. 3, 572, 2023.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Vellinga, A, Luke-Currier, A, Garzón-Orjuela, N, Aabenhus, R, Anastasaki, M, Balan, A, Böhmer, F, Lang, VB, Chlabicz, S, Coenen, S, García-Sangenís, A, Kowalczyk, A, Malania, L, Tomacinschii, A, van der Linde, SR, Bongard, E, Butler, CC, Goossens, H & van der Velden, AW 2023, 'Disease-Specific Quality Indicators for Outpatient Antibiotic Prescribing for Respiratory Infections (ESAC Quality Indicators) Applied to Point Prevalence Audit Surveys in General Practices in 13 European Countries', Antibiotics, vol. 12, no. 3, 572. https://doi.org/10.3390/antibiotics12030572

APA

Vellinga, A., Luke-Currier, A., Garzón-Orjuela, N., Aabenhus, R., Anastasaki, M., Balan, A., Böhmer, F., Lang, V. B., Chlabicz, S., Coenen, S., García-Sangenís, A., Kowalczyk, A., Malania, L., Tomacinschii, A., van der Linde, S. R., Bongard, E., Butler, C. C., Goossens, H., & van der Velden, A. W. (2023). Disease-Specific Quality Indicators for Outpatient Antibiotic Prescribing for Respiratory Infections (ESAC Quality Indicators) Applied to Point Prevalence Audit Surveys in General Practices in 13 European Countries. Antibiotics, 12(3), [572]. https://doi.org/10.3390/antibiotics12030572

Vancouver

Vellinga A, Luke-Currier A, Garzón-Orjuela N, Aabenhus R, Anastasaki M, Balan A et al. Disease-Specific Quality Indicators for Outpatient Antibiotic Prescribing for Respiratory Infections (ESAC Quality Indicators) Applied to Point Prevalence Audit Surveys in General Practices in 13 European Countries. Antibiotics. 2023;12(3). 572. https://doi.org/10.3390/antibiotics12030572

Author

Vellinga, Akke ; Luke-Currier, Addiena ; Garzón-Orjuela, Nathaly ; Aabenhus, Rune ; Anastasaki, Marilena ; Balan, Anca ; Böhmer, Femke ; Lang, Valerija Bralić ; Chlabicz, Slawomir ; Coenen, Samuel ; García-Sangenís, Ana ; Kowalczyk, Anna ; Malania, Lile ; Tomacinschii, Angela ; van der Linde, Sanne R. ; Bongard, Emily ; Butler, Christopher C. ; Goossens, Herman ; van der Velden, Alike W. / Disease-Specific Quality Indicators for Outpatient Antibiotic Prescribing for Respiratory Infections (ESAC Quality Indicators) Applied to Point Prevalence Audit Surveys in General Practices in 13 European Countries. In: Antibiotics. 2023 ; Vol. 12, No. 3.

Bibtex

@article{144ed44af36c41848b76773ffe79742d,
title = "Disease-Specific Quality Indicators for Outpatient Antibiotic Prescribing for Respiratory Infections (ESAC Quality Indicators) Applied to Point Prevalence Audit Surveys in General Practices in 13 European Countries",
abstract = "Up to 80% of antibiotics are prescribed in the community. An assessment of prescribing by indication will help to identify areas where improvement can be made. A point prevalence audit study (PPAS) of consecutive respiratory tract infection (RTI) consultations in general practices in 13 European countries was conducted in January–February 2020 (PPAS-1) and again in 2022 (PPAS-4). The European Surveillance of Antibiotic Consumption quality indicators (ESAC-QI) were calculated to identify where improvements can be made. A total of 3618 consultations were recorded for PPAS-1 and 2655 in PPAS-4. Bacterial aetiology was suspected in 26% (PPAS-1) and 12% (PPAS-4), and an antibiotic was prescribed in 30% (PPAS-1) and 16% (PPAS-4) of consultations. The percentage of adult patients with bronchitis who receive an antibiotic should, according to the ESAC-QI, not exceed 30%, which was not met by participating practices in any country except Denmark and Spain. For patients (≥1) with acute upper RTI, less than 20% should be prescribed an antibiotic, which was achieved by general practices in most countries, except Ireland (both PPAS), Croatia (PPAS-1), and Greece (PPAS-4) where prescribing for acute or chronic sinusitis (0–20%) was also exceeded. For pneumonia in adults, prescribing is acceptable for 90–100%, and this is lower in most countries. Prescribing for tonsillitis (≥1) exceeded the ESAC-QI (0–20%) in all countries and was 69% (PPAS-1) and 75% (PPAS-4). In conclusion, ESAC-QI applied to PPAS outcomes allows us to evaluate appropriate antibiotic prescribing by indication and benchmark general practices and countries.",
keywords = "antibiotic prescribing, audit, primary health care, quality in healthcare, respiratory infections",
author = "Akke Vellinga and Addiena Luke-Currier and Nathaly Garz{\'o}n-Orjuela and Rune Aabenhus and Marilena Anastasaki and Anca Balan and Femke B{\"o}hmer and Lang, {Valerija Brali{\'c}} and Slawomir Chlabicz and Samuel Coenen and Ana Garc{\'i}a-Sangen{\'i}s and Anna Kowalczyk and Lile Malania and Angela Tomacinschii and {van der Linde}, {Sanne R.} and Emily Bongard and Butler, {Christopher C.} and Herman Goossens and {van der Velden}, {Alike W.}",
note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",
year = "2023",
doi = "10.3390/antibiotics12030572",
language = "English",
volume = "12",
journal = "Antibiotics",
issn = "2079-6382",
publisher = "M D P I AG",
number = "3",

}

RIS

TY - JOUR

T1 - Disease-Specific Quality Indicators for Outpatient Antibiotic Prescribing for Respiratory Infections (ESAC Quality Indicators) Applied to Point Prevalence Audit Surveys in General Practices in 13 European Countries

AU - Vellinga, Akke

AU - Luke-Currier, Addiena

AU - Garzón-Orjuela, Nathaly

AU - Aabenhus, Rune

AU - Anastasaki, Marilena

AU - Balan, Anca

AU - Böhmer, Femke

AU - Lang, Valerija Bralić

AU - Chlabicz, Slawomir

AU - Coenen, Samuel

AU - García-Sangenís, Ana

AU - Kowalczyk, Anna

AU - Malania, Lile

AU - Tomacinschii, Angela

AU - van der Linde, Sanne R.

AU - Bongard, Emily

AU - Butler, Christopher C.

AU - Goossens, Herman

AU - van der Velden, Alike W.

N1 - Publisher Copyright: © 2023 by the authors.

PY - 2023

Y1 - 2023

N2 - Up to 80% of antibiotics are prescribed in the community. An assessment of prescribing by indication will help to identify areas where improvement can be made. A point prevalence audit study (PPAS) of consecutive respiratory tract infection (RTI) consultations in general practices in 13 European countries was conducted in January–February 2020 (PPAS-1) and again in 2022 (PPAS-4). The European Surveillance of Antibiotic Consumption quality indicators (ESAC-QI) were calculated to identify where improvements can be made. A total of 3618 consultations were recorded for PPAS-1 and 2655 in PPAS-4. Bacterial aetiology was suspected in 26% (PPAS-1) and 12% (PPAS-4), and an antibiotic was prescribed in 30% (PPAS-1) and 16% (PPAS-4) of consultations. The percentage of adult patients with bronchitis who receive an antibiotic should, according to the ESAC-QI, not exceed 30%, which was not met by participating practices in any country except Denmark and Spain. For patients (≥1) with acute upper RTI, less than 20% should be prescribed an antibiotic, which was achieved by general practices in most countries, except Ireland (both PPAS), Croatia (PPAS-1), and Greece (PPAS-4) where prescribing for acute or chronic sinusitis (0–20%) was also exceeded. For pneumonia in adults, prescribing is acceptable for 90–100%, and this is lower in most countries. Prescribing for tonsillitis (≥1) exceeded the ESAC-QI (0–20%) in all countries and was 69% (PPAS-1) and 75% (PPAS-4). In conclusion, ESAC-QI applied to PPAS outcomes allows us to evaluate appropriate antibiotic prescribing by indication and benchmark general practices and countries.

AB - Up to 80% of antibiotics are prescribed in the community. An assessment of prescribing by indication will help to identify areas where improvement can be made. A point prevalence audit study (PPAS) of consecutive respiratory tract infection (RTI) consultations in general practices in 13 European countries was conducted in January–February 2020 (PPAS-1) and again in 2022 (PPAS-4). The European Surveillance of Antibiotic Consumption quality indicators (ESAC-QI) were calculated to identify where improvements can be made. A total of 3618 consultations were recorded for PPAS-1 and 2655 in PPAS-4. Bacterial aetiology was suspected in 26% (PPAS-1) and 12% (PPAS-4), and an antibiotic was prescribed in 30% (PPAS-1) and 16% (PPAS-4) of consultations. The percentage of adult patients with bronchitis who receive an antibiotic should, according to the ESAC-QI, not exceed 30%, which was not met by participating practices in any country except Denmark and Spain. For patients (≥1) with acute upper RTI, less than 20% should be prescribed an antibiotic, which was achieved by general practices in most countries, except Ireland (both PPAS), Croatia (PPAS-1), and Greece (PPAS-4) where prescribing for acute or chronic sinusitis (0–20%) was also exceeded. For pneumonia in adults, prescribing is acceptable for 90–100%, and this is lower in most countries. Prescribing for tonsillitis (≥1) exceeded the ESAC-QI (0–20%) in all countries and was 69% (PPAS-1) and 75% (PPAS-4). In conclusion, ESAC-QI applied to PPAS outcomes allows us to evaluate appropriate antibiotic prescribing by indication and benchmark general practices and countries.

KW - antibiotic prescribing

KW - audit

KW - primary health care

KW - quality in healthcare

KW - respiratory infections

U2 - 10.3390/antibiotics12030572

DO - 10.3390/antibiotics12030572

M3 - Journal article

C2 - 36978439

AN - SCOPUS:85151689025

VL - 12

JO - Antibiotics

JF - Antibiotics

SN - 2079-6382

IS - 3

M1 - 572

ER -

ID: 347475429